CellSight Technologies
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, CellSight Technologies sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
CellSight Technologies: 8 sponsored US clinical trials, 5 recruiting.
CellSight Technologies sponsors 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit, with 1 trials.
Upper-quartile sponsor footprint
CellSight Technologies sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
NCT06107374
Test-retest Evaluation of [18F]F-AraG PET
NCT06084806
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
NCT04260256
Imaging Immune Activation in COVID-19
NCT04815096
Imaging Immune Activation in HIV by PET-MR
NCT03684655
Detection of Graft Versus Host Disease With [18F]F-AraG
NCT03367962
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT03129061
Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
NCT02323893
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 5 |
What is open in the CellSight Technologies pipeline
5 recruiting of 8 indexed (63% open); 3 completed (38%).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
CellSight Technologies: open-pipeline peers nationwide
Peers matched on 8 registered trials and 63% open enrollment, not the therapeutic-area sidebar.
CellSight Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 63% open enrollment (± trial volume)
- Canadian Cancer Trials Group · 63% recruiting · 16 trials
- Cook Children's Health Care System · 63% recruiting · 8 trials
- Nurix Therapeutics · 63% recruiting · 8 trials
- Pierre Fabre Medicament · 63% recruiting · 8 trials
Related
What to do with this CellSight Technologies page
8 registered trials is a research-attention snapshot, not an endorsement of CellSight Technologies or any single study.
- 5 of CellSight Technologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit is the condition CellSight Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. CellSight Technologies pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.